Chemobrain: A translational challenge for neurotoxicology

NeuroToxicology

Volumn 29, Issue 5, 2008, Pages 891-898

  Weiss, Bernard ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cancer; Chemobrain; Chemotherapy; Cognitive dysfunction; Computerized testing; Motor function; Sensory function

Indexed keywords

ACRYLAMIDE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BUSULFAN; CARMUSTINE; CHLORMETHINE DERIVATIVE; CISPLATIN; IFOSFAMIDE; INTERLEUKIN 2; METHOTREXATE; METHYLMERCURY; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; VINCA ALKALOID; VINCRISTINE; VOLATILE ORGANIC COMPOUND;

ARTICLE; CANCER CHEMOTHERAPY; COGNITIVE DEFECT; COLOR VISION DEFECT; CONFUSION; DEPRESSION; DISORIENTATION; EYE TOXICITY; HALLUCINATION; HUMAN; IRRITABILITY; LEUKOENCEPHALOPATHY; MOTOR PERFORMANCE; NEUROPATHY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NEUROTOXICOLOGY; NONHUMAN; OTOTOXICITY; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; PERSONALITY; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SMELLING; SOMATOSENSORY SYSTEM; TREMOR;

ANIMALS; BRAIN; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; TOXICOLOGY;

EID: 52149120538     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2008.03.009     Document Type: Article

References (71)

1. Ahles T.A., and Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7 (2007) 192-201
2. Ahlskog J.E. Beating a dead horse: dopamine and Parkinson disease. Neurology 69 (2007) 1701-1711
3. Antunes M.B., Bowler R., and Doty R.L. San Francisco/Oakland bay bridge welder study: olfactory function. Neurology 69 (2007) 1278-1284
4. Beckett W.S., Chamberlain D., Hallman E., May J., Hwang S.A., Gomez M., et al. Hearing conservation for farmers: source apportionment of occupational and environmental factors contributing to hearing loss. J Occup Environ Med 42 (2000) 806-813
5. Bensmaia S.J., Leung Y.Y., Hsiao S.S., and Johnson K.O. Vibratory adaptation of cutaneous mechanoreceptive afferents. J Neurophysiol 94 (2005) 3023-3036
6. Bernhardson B.M., Tishelman C., and Rutqvist L.E. Chemosensory changes experienced by patients undergoing cancer chemotherapy: a qualitative interview study. J Pain Symptom Manage 34 (2007) 403-412
7. Bleecker M.L., Ford D.P., Vaughan C.G., Walsh K.S., and Lindgren K.N. The association of lead exposure and motor performance mediated by cerebral white matter change. Neurotoxicology 28 (2007) 318-323
8. Bowler R.M., Gysens S., Diamond E., Nakagawa S., Drezgic M., and Roels H.A. Manganese exposure: neuropsychological and neurological symptoms and effects in welders. Neurotoxicology 27 (2006) 315-326
9. Burbacher T.M., Grant K.S., Mayfield D.B., Gilbert S.G., and Rice D.C. Prenatal methylmercury exposure affects spatial vision in adult monkeys. Toxicol Appl Pharmacol 208 (2005) 21-28
10. Castellon S.A., Ganz P.A., Bower J.E., Petersen L., Abraham L., and Greendale G.A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26 (2004) 955-969
11. Cavaletti G., Bogliun G., Marzorati L., Zincone A., Piatti M., Colombo N., et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 61 (2003) 1297-1300
12. Cavaletti G., Frigeni B., Lanzani F., Piatti M., Rota S., Briani C., et al. The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the national cancer institute-common toxicity scale. J Peripher Nerv Syst 12 (2007) 210-215
13. Chandrashekar J., Hoon M.A., Ryba N.J., and Zuker C.S. The receptors and cells for mammalian taste. Nature 444 (2006) 288-294
14. Chang S.J., Chen C.J., Lien C.H., and Sung F.C. Hearing loss in workers exposed to toluene and noise. Environ Health Perspect 114 (2006) 1283-1286
15. Chelonis J.J., Daniels-Shaw J.L., Blake D.J., and Paule M.G. Developmental aspects of delayed matching-to-sample task performance in children. Neurotoxicol Teratol 22 (2000) 683-694
16. Collie A., Darekar A., Weissgerber G., Toh M.K., Snyder P.J., Maruff P., et al. Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated phase I study. Contemp Clin Trials 28 (2007) 391-400
17. Dietrich J., Han R., Yang Y., Mayer-Proschel M., and Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5 (2006) 22
18. Djordjevic J., Jones-Gotman M., De Sousa K., and Chertkow H. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging (2007)
19. Dorsey C.D., Lee B.K., Bolla K.I., Weaver V.M., Lee S.S., Lee G.S., et al. Comparison of patella lead with blood lead and tibia lead and their associations with neurobehavioral test scores. J Occup Environ Med 48 (2006) 489-496
20. Duke J., McEvoy M., Sibbritt D., Guest M., Smith W., and Attia J. Vibrotactile threshold measurement for detecting peripheral neuropathy: defining variability and a normal range for clinical and research use. Diabetologia 50 (2007) 2305-2312
21. Eisner A., and Incognito L.J. The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen. Vision Res 46 (2006) 1816-1822
22. Ellingsen D.G., Bast-Pettersen R., Efskind J., and Thomassen Y. Neuropsychological effects of low mercury vapor exposure in chloralkali workers. Neurotoxicology 22 (2001) 249-258
23. Fechter L.D., and Pouyatos B. Ototoxicity. Environ Health Perspect 113 (2005) A443-A444
24. Fray P.J., and Robbins T.W. CANTAB battery: proposed utility in neurotoxicology. Neurotoxicol Teratol 18 (1996) 499-504
25. Froehlich T.E., Lanphear B.P., Dietrich K.N., Cory-Slechta D.A., Wang N., and Kahn R.S. Interactive effects of a DRD4 polymorphism, lead, and sex on executive functions in children. Biol Psychiatry 62 (2007) 243-249
26. Fuente A., and McPherson B. Organic solvents and hearing loss: the challenge for audiology. Int J Audiol 45 (2006) 367-381
27. Gobba F. Occupational exposure to chemicals and sensory organs: a neglected research field. Neurotoxicology 24 4-5 (2003) 675-691
28. Goldberg A.N., Shea J.A., Deems D.A., and Doty R.L. A ChemoSensory questionnaire for patients treated for cancer of the head and neck. Laryngoscope 115 (2005) 2077-2086
29. Hartman A., van den Bos C., Stijnen T., and Pieters R. Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer. Pediatr Blood Cancer (2007)
30. Hayes R.D., and Merigan W.H. Mechanisms of sensitivity loss due to visual cortex lesions in humans and macaques. Cereb Cortex 17 (2007) 1117-1128
31. Haymes S.A., Roberts K.F., Cruess A.F., Nicolela M.T., LeBlanc R.P., Ramsey M.S., et al. The letter contrast sensitivity test: clinical evaluation of a new design. Invest Ophthalmol Vis Sci 47 (2006) 2739-2745
32. Hochberg F., Miller G., Valenzuela R., McNelis S., Crump K.S., Covington T., et al. Late motor deficits of Chilean manganese miners: a blinded control study. Neurology 47 (1996) 788-795
33. Hurria A., Goldfarb S., Rosen C., Holland J., Zuckerman E., Lachs M.S., et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat 98 (2006) 343-348
34. Hutton J.L., Baracos V.E., and Wismer W.V. Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage 33 (2007) 156-165
35. Iregren A., Andersson M., and Nylen P. Color vision and occupational chemical exposures: I. an overview of tests and effects. Neurotoxicology 23 (2002) 719-733
36. Jazbec S., Pantelis C., Robbins T., Weickert T., Weinberger D.R., and Goldberg T.E. Intra-dimensional/extra-dimensional set-shifting performance in schizophrenia: impact of distractors. Schizophr Res 89 (2007) 339-349
37. Kaufman K.R., Brey R.H., Chou L.S., Rabatin A., Brown A.W., and Basford J.R. Comparison of subjective and objective measurements of balance disorders following traumatic brain injury. Med Eng Phys 28 (2006) 234-239
38. Knight K.R., Kraemer D.F., Winter C., and Neuwelt E.A. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25 (2007) 1190-1195
39. Lebel J., Mergler D., Branches F., Lucotte M., Amorim M., Larribe F., et al. Neurotoxic effects of low-level methylmercury contamination in the Amazonian basin. Environ Res 79 (1998) 20-32
40. Letz R., Gerr F., Cragle D., Green R.C., Watkins J., and Fidler A.T. Residual neurologic deficits 30 years after occupational exposure to elemental mercury. Neurotoxicology 21 (2000) 459-474
41. LoPachin R.M., Gavin T., Geohagen B.C., and Das S. Neurotoxic mechanisms of electrophilic type-2 alkenes: soft interactions described by quantum mechanical parameters. Toxicol Sci 98 (2007) 561-570
42. Lynch III J.J., Silveira L.C., Perry V.H., and Merigan W.H. Visual effects of damage to P ganglion cells in macaques. Vis Neurosci 8 (1992) 575-583
43. Maurissen J.P.J., and Weiss B. Vibration sensitivity as an index of somato-sensory function in monkeys and humans. In: Spencer P.S., and Schaumberg H.H. (Eds). Experimental and Clinical Neurotoxicology (1980), Williams and Wilkins
44. Maurissen J.P. Psychophysical testing in human populations exposed to neurotoxicants. Neurobehav Toxicol Teratol 7 (1985) 309-317
45. Maurissen J.P., and Chrzan G.J. One-year reliability of vibration sensitivity thresholds in human beings. J Neurol Sci 90 (1989) 325-334
46. Mergler D., and Beauvais B. Olfactory threshold shift following controlled 7-hour exposure to toluene and/or xylene. Neurotoxicology 13 (1992) 211-215
47. Newland M.C. Quantification of motor function in toxicology. Toxicol Lett 43 (1988) 295-319
48. Odkvist L.M., Moller C., and Thuomas K.A. Otoneurologic disturbances caused by solvent pollution. Otolaryngol Head Neck Surg 106 (1992) 687-692
49. Postma T.J., Aaronson N.K., Heimans J.J., Muller M.J., Hildebrand J.G., Delattre J.Y., et al. EORTC Quality of Life Group. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41 (2005) 1135-1139
50. Ravasco P. Aspects of taste and compliance in patients with cancer. Eur J Oncol Nurs 9 Suppl. 2 (2005) S84-S91
51. Reinders-Messelink H.A., Schoemaker M.M., Snijders T.A., Goeken L.N., Bokkerink J.P., and Kamps W.A. Analysis of handwriting of children during treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 37 (2001) 393-399
52. Rice D.C., and Gilbert S.G. Effects of developmental methylmercury exposure or lifetime lead exposure on vibration sensitivity function in monkeys. Toxicol Appl Pharmacol 134 (1995) 161-169
53. Rohlman D.S., Gimenes L.S., Eckerman D.A., Kang S.K., Farahat F.M., and Anger W.K. Development of the behavioral assessment and research system (BARS) to detect and characterize neurotoxicity in humans. Neurotoxicology 24 (2003) 523-531
54. Rohlman D.S., Lasarev M., Anger W.K., Scherer J., Stupfel J., and McCauley L. Neurobehavioral performance of adult and adolescent agricultural workers. Neurotoxicology 28 (2007) 374-380
55. Rosenblum S. The development and standardization of the children activity scales (ChAS-P/T) for the early identification of children with developmental coordination disorders. Child Care Health Dev 32 (2006) 619-632
56. Savic G., Bergstrom E.M., Davey N.J., Ellaway P.H., Frankel H.L., Jamous A., et al. Quantitative sensory tests (perceptual thresholds) in patients with spinal cord injury. J Rehabil Res Dev 44 (2007) 77-82
57. Schiff D., and Wen P. Central nervous system toxicity from cancer therapies. Hematol Oncol Clin North Am 20 (2006) 1377-1398
58. Schmid K.E., Kornek G.V., Scheithauer W., and Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 51 (2006) 19-40
59. Schreiber J.S., Hudnell H.K., Geller A.M., House D.E., Aldous K.M., Force M.S., et al. Apartment residents' and day care workers' exposures to tetrachloroethylene and deficits in visual contrast sensitivity. Environ Health Perspect 110 (2002) 655-664
60. Slikker Jr. W., Beck B.D., Cory-Slechta D.A., Paule M.G., Anger W.K., and Bellinger D. Cognitive tests: interpretation for neurotoxicity? (workshop summary). Toxicol Sci 58 (2000) 222-234
61. Spinelli S., Pennanen L., Dettling A.C., Feldon J., Higgins G.A., and Pryce C.R. Performance of the marmoset monkey on computerized tasks of attention and working memory. Brain Res Cogn Brain Res 19 (2004) 123-137
62. Taillibert S., Voillery D., and Bernard-Marty C. Chemobrain: Is systemic chemotherapy neurotoxic?. Curr Opin Oncol 19 (2007) 623-627
63. Tannock I.F., Ahles T.A., Ganz P.A., and Van Dam F.S. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22 (2004) 2233-2239
64. Tommerdahl M., Hester K.D., Felix E.R., Hollins M., Favorov O.V., Quibrera P.M., et al. Human vibrotactile frequency discriminative capacity after adaptation to 25 Hz or 200 Hz stimulation. Brain Res 1057 (2005) 1-9
65. Vannozzi G., Cereatti A., Mazza C., Benvenuti F., and Della Croce U. Extraction of information on elder motor ability from clinical and biomechanical data through data mining. Comput Methods Programs Biomed 88 (2007) 85-94
66. Vardy J., Rourke S., and Tannock I.F. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25 (2007) 2455-2463
67. Wampler M.A., Hamolsky D., Hamel K., Melisko M., and Topp K.S. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs 9 (2005) 189-193
68. Wefel J.S., Kayl A.E., and Meyers C.A. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 90 (2004) 1691-1696
69. White R.F., James K.E., Vasterling J.J., Letz R., Marans K., Delaney R., et al. Neuropsychological screening for cognitive impairment using computer-assisted tasks. Assessment 10 (2003) 86-101
70. Yokoo E.M., Valente J.G., Grattan L., Schmidt S.L., Platt I., and Silbergeld E.K. Low level methylmercury exposure affects neuropsychological function in adults. Environ Health 2 (2003) 8
71. Zoni S., Albini E., and Lucchini R. Neuropsychological testing for the assessment of manganese neurotoxicity: a review and a proposal. Am J Ind Med 50 (2007) 812-830